Song Minju
Department of Conservative Dentistry, College of Dentistry, Dankook University, Cheonan, Korea.
Restor Dent Endod. 2019 Nov 1;44(4):e42. doi: 10.5395/rde.2019.44.e42. eCollection 2019 Nov.
Antiresorptive drugs (ARDs), such as bisphosphonates or denosumab, that prevent bone resorption are widely used in patients with osteoporosis or with cancer that has metastasized to the bones. Although osteonecrosis of the jaw (ONJ) is a well-documented complication of ARD use, the benefits ARDs outweigh the complication. Thus, research has focused on finding ways to prevent or reduce the risk of developing ONJ. Dentists, as part of a multi-professional team, have a critical role in preventing ONJ. However, many dentists tend to hesitate to provide dental care to patients with ONJ, or tend to think that it is a problem to be dealt with by oral surgeons. This review gives an overview of ARD-related ONJ and provides the guidelines for dental care in patients taking ARDs to lower the risk of developing ONJ.
抗吸收药物（ARDs），如双膦酸盐或地诺单抗，可预防骨吸收，广泛用于骨质疏松症患者或已发生骨转移的癌症患者。尽管颌骨坏死（ONJ）是ARDs使用的一种有充分记录的并发症，但ARDs的益处超过了这种并发症。因此，研究集中在寻找预防或降低发生ONJ风险的方法。作为多专业团队的一员，牙医在预防ONJ方面起着关键作用。然而，许多牙医往往不愿为ONJ患者提供牙科护理，或者倾向于认为这是口腔外科医生要处理的问题。本综述概述了与ARDs相关的ONJ，并为服用ARDs的患者提供牙科护理指南，以降低发生ONJ的风险。
